Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale by Kovshoff, Hanna et al.
Reports of Perceived Adverse Events of Stimulant
Medication on Cognition, Motivation, and Mood:
Qualitative Investigation and the Generation of Items
for the Medication and Cognition Rating Scale
Hanna Kovshoff, PhD,1 Tobias Banaschewski, MD, PhD,2 Jan K. Buitelaar, MD, PhD,3 Sara Carucci, MD,4
David Coghill, MBChB, MD, FRCPsych,5,6 Marina Danckaerts, MD, PhD,7 Ralf W. Dittmann, MD, PhD,8
Bruno Falissard, MD, PhD9 Dina Gojkovic Grimshaw, PhD,1 Chris Hollis, PhD, FRCPsych,10
Sarah Inglis, PhD,11 Kerstin Konrad, PhD,12,13 Elizabeth Liddle, PhD,10 Suzanne McCarthy, PhD,14
Peter Nagy, MD,15 Margaret Thompson, MD, FRCPsych,1 Ian C.K. Wong, PhD, FRCPCH,16,17
Alessandro Zuddas, MD,4 and Edmund J.S. Sonuga-Barke, PhD1,18
Abstract
Objective: There is no questionnaire to specifically monitor perceived adverse events of methylphenidate (MPH) on cog-
nition, motivation, and mood. The current study therefore had two goals. First, to harvest accounts of such putative events
from transcripts of interviews in samples enriched for such potential experiences. Second, to use the derived data to generate
items for a new questionnaire that can be used for monitoring such events in medication trials or routine clinical care.
Methods: Following a literature search aimed at identifying associations between MPH and cognition and/or motivation, a
qualitative semistructured interview was designed to focus specifically on the domains of cognition (i.e., reasoning, depth/
breadth of thinking, intellectual capacity, and creativity) and motivation (i.e., drive, effort, and attitudes toward rewards/
incentives). Interviews were conducted with 45 participants drawn from the following four groups: (a) clinicians, child and
adolescent psychiatrists, and pediatricians specializing in attention-deficit/hyperactivity disorder (ADHD) (n = 15); (2)
teachers, with experience of teaching at least 10 medicated children with ADHD (n = 10); (3) parents of children with ADHD
(n = 8) treatedwithMPH; and (4) adolescents/adults with ADHD (n = 12). Purposeful samplingwas used to selectively recruit
ADHD participants whose histories suggested a degree of vulnerability to MPH adverse events. Data were analyzed using a
deductive approach to content analysis.
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Results:Whilewe probed purposefully for cognitive andmotivational adverse events, a third domain, related tomood, emerged
from the reports. Therefore, three domains, each with a number of subdomains, were identified from the interview accounts: (i)
Cognition (six subdomains; attention/concentration, changes in thinking, reduced creativity, sensory overload, memory, slower
processing speed); (ii) motivation (four subdomains; loss of intrinsic motivation for goal-directed activities, external locus of
control, lackof effort/engagement in daily tasks, increased focus on incentives); and (iii)mood (three subdomains; dampeningof
spontaneity/flat affect, mood dysregulation, increased anxiety/edginess). On the basis of these reports, 34 items were specified
and incorporated into a prototype questionnaire, which was piloted and refined on the basis of field-testing.
Conclusions: Items were identified that capture potential/perceived cognitive, motivational, and mood-related adverse
events ofMPH. The items generated will allow us to further develop and psychometrically examine their prevalence, and the
extent to which they are associated with medication adherence, treatment outcome, impairment, and other reported adverse
events (e.g., loss of appetite/cardiovascular effects).
Introduction
Methylphenidate (MPH), along with other stimulant andnonstimulant medications, is recommended for the treatment
of attention-deficit/hyperactivity disorder (ADHD) based on evidence
of efficacy from randomized controlled trials (NICE 2008; Graham
et al. 2011). While generally well tolerated (Faraone and Buitelaar
2010), MPH has been associated with a range of adverse events/
reactions over both the short and medium/long term (Cortese et al.
2013). The most common of these include loss of appetite, restricted
growth, and weight suppression (Faraone et al. 2008), increases in
blood pressure and heart rate (Graham and Coghill 2008; Hammer-
ness et al. 2011), sleep disturbances (Schachter et al. 2001), and
possible exacerbation of existing tics (Pringsheim and Steeves 2011).
Short-term positive effects of MPH on cognition and motivation
are well documented in neuropsychological studies (Volkow et al.
2004; Coghill et al. 2014). Stimulant medication may improve some
cognitive functions (attention), but there are also reports that it im-
pairs others such as divergent thinking (Douglas et al. 1995), flexi-
bility and planning (Advocat 2010), or creativity (Farah et al. 2008),
at least in some cases. In terms of adverse events, laboratory studies
provide some evidence of cognitive rigidity (Solanto 1984), reward
desensitization (Andersen et al. 2008), altered attribution style/sense
of agency (Carlson et al. 1993), and/or impaired memory (Sprague
et al. 1977) with some of these cognitive changes being dose de-
pendent such that higher doses lead tomore impairing adverse events.
Consistent with this notion, there are also reports in the literature
of higher doses of MPH being more effective for behavioral man-
agement but impacting negatively on executive attention control
and working memory (Berridge et al. 2006). Thus, if clinicians and
families prioritize behavioral targets in treatment goals, this may
limit the potential impact of MPH on academic achievement more
generally, given the lower doses required for cognitive enhancement
(c.f., Hale et al. 2011). Finally, there have also been reports of
adverse emotional events (e.g., Pelham and Hoza 1996), which are
known to play a role in both cognitive ability andmotivational style.
While there are some reports that adverse events of MPH may
manifest as changes in cognition and motivation, these may not be
mentioned or questioned in the course of routine clinical practice.
Regulatory bodies like the European Medicines Agency (EMA
2010) require the monitoring and collection of pharmacovigilance
data, which involves the monitoring of medication effects after
licensing for adverse effects not reported or found in clinical trials.
These data are required to be collated for potential adverse effects/
events during the clinical development of psychotropic compounds
and through postmarketing surveillance for up to 2 years in adult
and pediatric populations. However, it is not well understood how
consistently cognitive adverse events are reported once the regu-
latory monitoring and reporting period for the medication has
ended (post-2 years for ADHD medication) as it depends on cli-
nicians and patients spontaneously identifying and reporting these
as adverse events or side effects (e.g., through yellow card reporting
in the UK-MHRA 2015).
While typical acute adverse effect scales for stimulant treat-
ments such as the Safety Monitoring Uniform Report Form
(SMURF; Greenhill et al. 2004) or the Side Effects Scale (Barkley
et al. 1990) collate information such as ‘‘stares a lot,’’ ‘‘talks less,’’
‘‘prone to crying,’’ ‘‘anxious,’’ or ‘‘sadness,’’ detailed standardized
assessments of potential adverse events of MPH across broader
psychological domains—for instance, those relating to cognition,
motivation, and mood—are still lacking. Nevertheless, this may be
of particular importance as it has been suggested that cognitive,
motivational, and emotional adverse events are significant reasons
for lack of adherence with, or discontinuation of, long-term med-
ication use, particularly during adolescence (Charach et al. 2004,
2008).
The lack of routine monitoring of cognitive and motivational
adverse events in everyday clinical practice could be linked to a
more general lack of systematic monitoring of treatment response,
as many clinicians still rely on spontaneous reporting of adverse
events by patients and parents (Kovshoff et al. 2012). It is also
likely due to the fact that compared to other elements of the putative
MPH adverse event or effect profile, the concept of cognitive or
motivational adverse events remains both poorly defined and ar-
ticulated, with no standardized approach to reporting available.
Other potential reasons for the lack of focus on cognitive and
motivational adverse events include that (i) they may be more
difficult to observe than typical adverse events; (ii) they might be
experienced as subtle and/or vague signs that are difficult to de-
scribe and self-report, particularly by younger children; (iii) they
may be rare; (iv) it may be difficult to establish a causal link (if one
exists) between these adverse events and the medication, or to
differentiate between concerns specific to MPH and core or sec-
ondary symptoms of the ADHD itself; or (v) the benefits of MPH
experienced by the patient and families may outweigh any potential
cognitive or motivational adverse events experienced, and hence,
these adverse events may not be seen as sufficiently significant to
warrant reporting.
The current article represents the first stage in a project to
investigate cognitive and motivational adverse events following
stimulant medication use as part of the European Commission 7th
Framework Programme for research; Attention Deficit/hyperac-
tivity Drugs Use Chronic Effects (ADDUCE; www.adhd-adduce.
org—Grant no. 260576) (Murray et al. 2013; Inglis et al.
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submitted). Within this larger program of research, one subproject
involved the development of a questionnaire to systematically
measure putative cognitive and motivational adverse events fol-
lowing MPH treatment. This will eventually allow us to esti-
mate the prevalence of such effects in the general population of
individuals treated with MPH, explore the association with ad-
herence and treatment outcome, and assess their impact on daily
functioning.
Aims and Objectives
The goal of this study was to generate items that characterize
potential adverse events that may be associated with MPH as per-
ceived by the patient, family, clinicians, or teachers that impact on
cognition and/or motivation. Our aim was to elicit examples of
potential adverse cognitive and motivational events that, at least to
our participants, were believed to be associated with MPH treat-
ment, so that these accounts could provide candidate items for a
questionnaire that could then be validated in a larger representative
sample. We first aimed to collect multiple examples and experi-
ences of cognitive and motivational adverse events, including the
key stakeholder groups in ADHD management (i.e., children and
adults with ADHD, parents of children with ADHD, teachers, and
clinicians). The views and experiences described were then trans-
formed into items that could be used to elicit quantifiable responses
on a questionnaire. The questionnaire was then piloted in a group of
children with ADHD and subsequently refined to ensure accept-
ability and accessibility of items and concepts.
Methods
Participants
The research protocol and all study documents received Uni-
versity of Southampton (ERGO Study ID 681; RGO Ref 8377) and
NHS Research Ethics Committee (REC Study ID: 11/SC/0541)
approval. Within this protocol, all participants were provided with
information sheets describing the aims and objectives of the study,
given the opportunity to reflect and ask questions about participa-
tion, and signed consent or assent forms describing how their in-
terview data would be used. They were also provided with debrief
forms outlining how to withdraw from the study if desired, obtain a
copy of the findings when the study was complete, and signposting
to additional services if required.
To maximize the chances of identifying a range of potential
cognitive and motivational experiences associated with MPH
treatment, and to ensure that we were able to saturate our data,
purposeful sampling of four independent groups of approximately
8–12 participants each, were recruited from within the South of
England; experienced ADHD clinicians, adults and adolescents
with ADHD who self-identified as having experienced unwanted
adverse events when taking MPH, parents of children with ADHD
who self-reported that their child experienced unwanted adverse
events when taking MPH, and experienced teachers of medicated
children with ADHD (e.g., from special needs classes, pupil re-
ferral units). Thus, all of the participants had personal or professional
experience with and/or history of general MPH adverse events.
The group of clinicians (n=15; 9 females, 6 males) with profes-
sional experience of treating ADHD consisted of six pediatricians,
seven child and adolescent psychiatrists, and two senior nurse pre-
scribers specializing in ADHD. They were included in the study if
they had a minimum of 5 years experience of prescribing MPH to
patients with ADHD and opportunities for the follow-up consulta-
tions where they would have had a chance to examine potential ad-
verse effects. Themean length of experience ofMPH prescribing was
12.0 years (standard deviation [SD]=6.6). Individuals with ADHD
(n=12; 7 females, 4 males, 1 preferred not to disclose) included three
adolescents (ages 12–17 years, mean age 14.6 years, SD = 2.5) and
nine adults who had undergone relatively extended treatment (i.e.,
more than 12 months of consecutive use) with MPH and self-
reported experiencing adverse events when taking the medication.
For parents of patients/individuals with ADHD (n= 8; 7 females,
1 male), inclusion criteria stipulated that they had a child who had
experienced evident adverse events while taking MPH (either past
or present, we included any form of event that was deemed un-
wanted or adverse in the eyes of patients or families). Teachers
(n = 10; 6 females, 4 males) who had significant experience of
teaching MPH-treated children with ADHD (min. 10 children)
were also interviewed. They had a mean duration of 6.4 years
(SD = 3.9) working with medicated children with ADHD. To en-
sure confidentiality, participants were ascribed unique anonymized
identifiers. These consisted of a letter referring to the category to
which they belonged (C= clinicians, P = parents, T = teachers,
AC= individuals with ADHD) and a number (e.g., C1 for Clinician
number 1).We recorded interviews and transcribed and coded them
immediately after interviewing the participants so that we were
able to sample to saturation (i.e., the point at which no new codes
were returned from the interview transcripts).
Interview procedure
The semistructured interview was developed by the research
team to include open-ended questions about potential cognitive
and motivational adverse events perceived to be directly related to
MPH (e.g., could you describe any positive/negative effect of
MPH on your thinking). After piloting the original interview
schedule with three participants, including one medicated adult
with ADHD, one clinician, and one parent of an adolescent with
ADHD, the final interview schedule comprised a total of 34
questions focusing on cognitive (n = 17) and motivational (n = 17)
adverse events. Interviewers encouraged participants to describe
any potential adverse events in their own words. When describing
an experience, interviewers took care to clarify whether the par-
ticipant believed the experience only appeared after or worsened
since starting MPH.
The participants were informed that the study was exploratory and
that the aim was to shed light on any cognitive and/or motivational
adverse events, which they may have noticed in their professional
practice and/or personal experience of MPH. Interviews were con-
ducted by postdoctoral-level researchers who had been trained to
conduct qualitative interviews and had extensive experience in this
technique. Interviews typically lasted for 60minutes and occurred at a
time and place that was convenient for participants (e.g., home, place
of work, or through telephone).
Data analysis
A content analysis approach to the data (Ritchie and Spencer
1993) was used as it provides a flexible and deductive method for
analyzing text data. For the current study, conventional content
analysis was used through which coding categories were derived
directly from the text (Hsieh and Shannon 2005). While our in-
terview was designed to gather information about positive and
negative effects of MPH, given our overall aim was to develop a
questionnaire measure of adverse events, only negative/adverse
experiences/events of MPH treatment were coded.
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In the first phase, two researchers familiarized themselves with
the transcripts through a thorough reading from beginning to end.
Then, the researcher who performed the main analysis read each
transcript carefully again, making notes, and highlighting the text
that described the adverse events of medication in the pre-
determined areas of cognition and motivation (e.g., memory, at-
tention, and creativity). The researcher then generated preliminary
codes from the first five transcripts from each participant group and
coded the remaining transcripts using these original codes, adding
new codes whenever new information was encountered that did not
fit in with the existing codes.
While coding, the researcher collapsed or combined lower level
codes to form higher level codes (for instance, ‘‘inability to take in
others,’’ ‘‘point of view,’’ and ‘‘fixation on thoughts/actions’’ were
combined into higher level code ‘‘rigidity of thought,’’ which then
formed part of ‘‘top-level’’ code ‘‘changes in thinking’’). During
this process, a complete detailed coding manual devised by the first
coder was scrutinized by the second. The second researcher inde-
pendently recoded 10% of the transcripts, effectively retesting all
of the codes. Any differences between the codings were discussed
until a mutual agreement on the final coding manual was achieved.
Results
Categories, domains and subdomains
Overall, at least one cognitive and/or motivational adverse ex-
perience of MPH was reported by 89% of participants interviewed
in this study (note that this figure does not relate to prevalence rates
of adverse events in the general ADHD population treated with
stimulants, but only in our highly selective purposeful sample).
Table 1 provides a summary of domains and subdomains by cate-
gory listed in order of frequency of report/nomination by partici-
pants (in descending order from the most commonly identified
adverse experience/event with the medication), alongside a proto-
typical statement and illustrative quote for each.
During the analysis stage, a third category of ‘‘mood’’-related
adverse events was added although it was not specifically probed in
the study. A total of 84% of participants were described cognitive,
80% mood related, and 51% motivational adverse events. A de-
tailed breakdown of these figures by category and participant group
is shown in Table 1. Table 2 represents a summary of categories and
domains.
Cognitive. Cognitive AEs were most commonly reported. Six
domains emerged, ordered according to frequency; (1) poorer at-
tention/concentration, (2) changes in thinking, (3) reduced crea-
tivity, (4) sensory overload, (5) poorer memory, and (6) slower
processing speed. (1) Negative events on attention/concentration
were most commonly cited and divided into the following three
subdomains: (i) zoning out/staring leading patients to experience a
lack of clarity of thought and tendency to stare into space for long
periods of time, (ii) hyper- or over-focusing particularly leading to
difficulties transitioning or dividing attention between tasks, and
(iii) increased distractibility. (2) Undesirable changes in thinking
patterns were the second most frequently mentioned domain of
cognitive adverse events with MPH treatment, and it included two
subdomains; (i) increased fixation on one’s thoughts, which in-
cluded the single-minded absorption in one’s thoughts and/or
preoccupation with doing things in a certain predetermined way
and (ii) rigid thinking led users to struggle to consider another’s
point of view or alternative ways of doing things.
(3) Reduced creativity was reported by individuals who de-
scribed a sensation of overly structured thinking experienced at the
expense of creativity. (4) The fourth cognitive domain involved
sensory overload. Here, respondents reported that their senses were
heightened often to an undesirable degree after taking MPH. This
led to a hyperawareness of surroundings, which was perceived as
negative and ultimately impacted on thinking, when experienced
acutely. (5) Poorer memory was reported by 18% of participants. In
particular, individuals described increased forgetfulness and trou-
ble remembering or recalling recent events. (6) The sixth and final
cognitive domain mentioned was slower processing speed; some
participants talked about responding to events more slowly, which
led to a dampening of their competitive drive, while others spoke of
slower thoughts, which were particularly problematic for those who
wished to be creative. Here, analytic depth was perceived to lead to
the negative sensation of a reduction in quick thinking and an in-
crease in the time it takes to process information.
Motivation. The motivation category had four domains. (1)
First, experiences/events related to loss of intrinsic motivation for
goal-directed activities referred to patients taking MPH, who de-
scribed themselves as more compliant and more able to complete
activities, but experiencing less intrinsic motivation. (2) The sec-
ond domain in relation to motivation was the development of an
external locus of control. Participants reported that some individuals
with ADHD may attribute behavior regulation to medication rather
than to their own ability. (3) Some individuals reportedMPH led to a
lack of effort/engagement with tasks, for example, MPH was per-
ceived to lead to increased difficulties initiating or participating in
everyday tasks such as tidying or homework. (4) Finally, some
Table 1. Number and Percentage of Participants Who
Identified Adverse Events in Each Group by Domain
Participants
with ADHD Parents Clinicians Teachers
N (12),
(%) N (8), (%)
N (15),
(%)
N (10),
(%)
Cognition 11 (92) 5 (62) 13 (87) 9 (90)
Motivation 9 (75) 4 (50) 7 (47) 6 (60)
Mood 9 (75) 5 (62) 12 (80) 8 (80)
ADHD, attention-deficit/hyperactivity disorder.
Table 2. Summary of Domains
Category Domain
Cognitive Slower attention/concentration
Changes in thinking
Reduced creativity
Sensory overload
Poorer memory
Slower processing speed
Dampening of mood/spontaneity
Mood Mood dysregulation
Sense of being different
Increased anxiety
Motivation Loss of intrinsic motivation for goal-directed
activities
External locus of control
Lack of effort/engagement in daily tasks
Increased focus on rewards/incentives
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participants noted that MPH users were more demanding of and
required increased focus on rewards/incentives to complete tasks on
medication. They also reported that medication led to a greater ex-
pectation and need for others to praise or reward them for activities.
Mood. A third domain, described as mood-related, emerged as
the secondmost frequently cited adverse event ofMPH. There were
three subdomains. (1) The most commonly cited being dampening
of spontaneity. This included descriptions of individuals losing
their spark and becoming dull or boring when medicated. (2) The
second most frequently described mood-related adverse event was
related to mood dysregulation. Mood swings, emotional lability,
and feelings of depression were reported. Secondary repercussions
of this involved individuals being unable to think about and focus
on tasks given their experience of negative affect. (3) Events related
to increased anxiety while on medication were also mentioned.
Here, participants gave the example of subjects choosing not to take
MPH on days likely to be stressful (e.g., test days or important
meetings) as they felt it would amplify and worsen anxiety.
Initial development of the prototype Medication and
Cognition Questionnaire. All of the domains and subdomains
described in the coding manual and listed in Table 3 were used to
develop prototypical questionnaire items for the Medication and
Cognition Questionnaire (MCQ). Two items per domain/sub-
domain were created.Where possible, these were paraphrased from
participants’ own words (Table 4).
The first draft of the questionnaire was piloted with 20 children
with ADHD, aged 7–16 years (mean = 11.2; SD= 2.69) partici-
pating in the ADDUCE project (www.adhd-adduce.org), who had
been taking MPH for 18 months. Following this pilot phase, it was
found that 20/34 items were not consistently understood by some of
the younger participants. A focus group of six typically developing
children aged 7 years, who did not have diagnosis of ADHD, was
formed to help generate age-appropriate phrasing for these items.
For example, the item ‘‘Had difficulty considering alternative ways
of doing things’’ was changed to ‘‘had trouble thinking of different
ways to do things (like when doing a maths problem)’’. The final
item set is listed in Table 4.
The final questionnaire is being piloted within the larger AD-
DUCE project trial at the 18-month data collection point across the
four European sites (United Kingdom, Hungary, Italy, and Ger-
many). These data will then be used to investigate the internal
consistency and factor loading of the items, and to further refine the
items as necessary, for example, to ensure they are developmentally
appropriate and understandable across a wide age range. We will
also assess the psychometric properties of the MCQ, including
conducting test–retest reliability with a subset of participants, and
through tests of concurrent (e.g., looking at the relationship with
mood measures) and predictive validity (looking at outcomes and
medication adherence across the sample).
Discussion
Our interviews with our purposively selected and nonrepresen-
tative sample of clinicians, teachers, parents, and individuals with
ADHD about their negative experiences and reports of MPH use,
provided descriptions of potential adverse events of MPH on
cognition, motivation, and mood, at least in most cases. The pur-
pose of our qualitative interview was to harvest an in-depth and
broad account of any potential cognitive or functional impact (re-
gardless of dose), in a sample of participants enriched for experi-
ence/knowledge of adverse events/reactions toMPH. That is to say,
participants all had direct (as in the case of patients) or indirect
experience of adverse events/reactions more generally.
Crucially, this was not a survey of adverse events associated with
MPH in a representative sample of MPH-treated ADHD patients,
and so, proportions of individuals reporting events cannot in any
way be equated with prevalence rates, for example, from controlled
clinical trials or postmarket reporting. Determination of prevalence
rates of these adverse events is currently being undertaken with the
MCQ as part of the ADDUCE 2-year longitudinal naturalistic
prospective pharmacovigilance study (Inglis et al. submitted) and
will be reported separately.
With these caveats in mind, our findings corroborate and extend
the conclusions of an emergent body of literature that has sought to
examine possible adverse impacts of stimulant medication from
patient and practitioner perspectives. Accordingly, Charach et al.
(2014) conducted qualitative interviews with 12 young people aged
12–15 years and their parents to investigate their attitudes toward
use of stimulant medication. While most participants noted the
benefits of stimulants in multiple domains, they also expressed
concerns about negative changes in their subjective experience and
feelings about themselves. They reported that their medication
caused them to feel less happy, quieter, weird, unsociable, and less
outgoing. They also noted other adverse events, including head-
aches and mood lability, which alongside the undesirable changes
in their sense of self led to a desire to discontinue medication.
Similarly, Meaux et al. (2006, p. 220) interviewed 15 college
students with ADHD about their experience of stimulant medica-
tion. While all participants agreed that stimulants improved their
concentration and focus, many also recounted that taking stimu-
lants involved a trade-off between any benefits of the medication
and undesirable cognitive, behavioral, social, and physiological
effects of the drug. In particular, they described feeling like ev-
erything was in slow motion, their daily experiences involved
feeling flat or monotone, and that the medication made them feel
unsociable and killed their personality.
As part of the ADHD VOICES Study, Singh et al. (2010) con-
ducted focus groups and 1:1 interviews with 16 young people with
ADHD onmedication to gather information about their experiences
of stimulant treatment. Generally, the participants in their study did
not report any specific adverse events of stimulant medication.
However, in their final report of this study, Singh (2012, p. 24)
acknowledges that a ‘‘small group of children’’ felt that stimulant
medication ‘‘gave them a ‘second personality.’’’
When taking into account the perspectives of not only patients
with ADHD but also parents, experienced clinicians, and teachers,
the participants in our study identified adverse events that they
perceived to be associated with MPH treatment and related to or
associated with cognition, motivational style, and mood. Interest-
ingly, participants in the current study also reported that individuals
with MPH treatment developed strategies to manage any unwanted
effects of the medication. For example, those who believed that
MPH exacerbated their anxiety would avoid taking their medi-
cation on days in which they were worried the impact of the
medication might impede performance. However, failure to take
prescribed medication may have other important costs to the indi-
vidual where enhanced attention and concentration are required.
Others were able to manage their medication use so that they chose
when was most suitable for them to take their medication. For
example, those who were required to be risk-taking or creative as
part of their jobs or sporting activities avoided taking the medica-
tion for key events, and took it only when they felt it would be
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desirable to slow down thinking, and some of our participants only
took it for tasks where creativity was not required.
Still others expressed uncertainty about whether the adverse
events they experienced could be directly attributed to the medi-
cation or to other causes such as puberty or comorbid mental ill-
nesses, or simply to a greater understanding or awareness of their
ADHD symptoms.
Limitations
While the participants in this study have introduced several in-
teresting avenues for future research and consideration, it is important
to note the caveats with which these data must be interpreted. This
research represents a specific and goal-oriented exercise in gathering
examples of adverse events associated with MPH treatment. For this
purpose, a comparison group of individuals who did not experience
negative effects of MPHwere not required as the ultimate goal was to
collate only the adverse events described during our interview study
to develop a measure of adverse events related to/associated with
MPH. This measure will now require testing in large, representative
samples of ADHD patients both on and off MPH medication, with
and without a positive adverse effect profile, to control for bias ef-
fects. Additional testing and refinement may also be required to en-
sure that the measure has good validity and developmental sensitivity
for both younger children and adult populations. Without this test of
the data, the adverse events reported here cannot and should not be
directly attributed to MPH.
Conclusions
Management and identification of these sorts of adverse events
require further attention and a more systematic and standardized
approach to disentangle some of the issues raised. Moreover, fur-
ther systematic study of these possible adverse events is also im-
portant to clarify their relationship with predictive/moderating
variables (e.g., comorbid conditions, personality traits, genetic
variance, and potential relationships with physiological side ef-
fects). It would also be of clinical importance to identify which
Table 3. MCQ Items
Over the last 4 weeks have you .
Not
at all
A
little
More
or less A lot Completely
Is this a problem
for you?
1. Over-focused on jobs you had to do 0 1 2 3 4 Yes No
2. Had trouble remembering recent experiences or events 0 1 2 3 4 Yes No
3. Had trouble thinking of different ways to do things (e.g., like
when you are doing a maths problem)
0 1 2 3 4 Yes No
4. Felt like you weren’t putting much effort into things 0 1 2 3 4 Yes No
5. Been anxious or worried 0 1 2 3 4 Yes No
6. Not been interested or excited to achieve your goals 0 1 2 3 4 Yes No
7. Been distracted 0 1 2 3 4 Yes No
8. Expected or wanted other people to praise or reward you 0 1 2 3 4 Yes No
9. Been emotional (e.g., had lots of strong feelings) 0 1 2 3 4 Yes No
10. Felt more boring and less exciting than usual 0 1 2 3 4 Yes No
11. Had a very sensitive sense of smell, touch, taste or hearing 0 1 2 3 4 Yes No
12. Been thinking slowly 0 1 2 3 4 Yes No
13. Been well behaved 0 1 2 3 4 Yes No
14. Noticed your thinking was fuzzy or confused 0 1 2 3 4 Yes No
15. Felt nervous or had butterflies in your stomach 0 1 2 3 4 Yes No
16. Not been creative 0 1 2 3 4 Yes No
17. Noticed your mood or temper kept changing 0 1 2 3 4 Yes No
18. Been sensitive to sights, sounds, or touch 0 1 2 3 4 Yes No
19. Been focused on doing things in a certain way 0 1 2 3 4 Yes No
20. Been forgetful 0 1 2 3 4 Yes No
21. Not been pushing yourself to work as hard or harder than
other people
0 1 2 3 4 Yes No
22. Needed and wanted to be rewarded for work/behaviour 0 1 2 3 4 Yes No
23. Been focused on your own thoughts (e.g., can’t get out
of your head)
0 1 2 3 4 Yes No
24. Not shown creativity 0 1 2 3 4 Yes No
25. Had trouble trying to understand other people’s views
or opinions
0 1 2 3 4 Yes No
26. Had slow reflexes or reacted slowly 0 1 2 3 4 Yes No
27. Found it difficult to think quickly 0 1 2 3 4 Yes No
28. Found it really hard to start your normal everyday tasks
(e.g., morning work or household chores)
0 1 2 3 4 Yes No
29. Been ‘‘good’’ 0 1 2 3 4 Yes No
30. Thought too hard or were lost in your own thoughts 0 1 2 3 4 Yes No
31. Stared at things or people 0 1 2 3 4 Yes No
32. Had no personality or ‘‘get-up-and-go’’ 0 1 2 3 4 Yes No
33. Not been making an effort 0 1 2 3 4 Yes No
34. Had trouble concentrating 0 1 2 3 4 Yes No
MCQ, Medication and Cognition Questionnaire.
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Table 4. Detailed Information About Each Domain and Subdomain in Order of Frequency (%) of Reporting
Dom Subdomain
N (%) of
participants
reporting Statement Detailed illustrative quote
Mood Dampening of mood/
spontaneity
31 (69%) Feel like I’d
lost spark
Actually some of the teenage boys complain that they are not
interesting when they are on MPH, they’ll say ‘‘I am really
chatty and girls like me when I am not on my MPH, and when
I take it yes I get more work done but I am too quiet, I am dull
and I don’t like it.’’ I’ve had a couple that asked to be taken
off it because girls find them boring (C1)
Personality dull I have an ADHD and that is the only way I know of myself,
that’s how I know I am being me, like you know you are
being you, and when I take meds I feel different which is
why I don’t like to think of it. With ADHD I feel like quite
an exceptional person and when I am off my meds I can
think of things creatively and people -when they see me off
my medication they know it’s me. When I am on my meds
[.] my personality, me is shut off (AC2)
Mood Mood dysregulation 21 (47%) Emotional I did cry more when I was on medication I think I was so tired,
I was tired and frustrated that I was tired so I got bit
emotional about things probably a week or so after I started
taking it (AC2)
Mood swings We have seen changes in mood, unexplained crying, scream-
ing, agitation, even on small doses of methylphenidate (C9)
Cog Attention/concentra-
tion (zoning out/
staring)
21 (47%) Thoughts foggy
or spacey
It’s like you’ve been asleep and you just woke up and your
head is all foggy. It’s like that it puts you in that sort of
mode . in a way like you smoked too many spliffs . so
it’s . fogs your head. it’s like you just feel like a zombie.
there’s much you can physically do, things that are in front
of you. I was off my head ‘‘oh what’s going on with my
concentration’’ (AC4)
Stare at things for
long periods
In some cases not only staring for a long period but they look
really withdrawn and non-reactive on very rare occasion
(C3)
Mot Loss of intrinsic
motivation
16 (36%) Less motivated to
achieve goals
I think I can attain something when I am on it, but the desire to
attain it is greater when I am off it [.] I find it easier to
attain a goal when on meds but to be honest I am personally
not that bothered about it then (AC3)
Less motivated
than usual
They sit down in a desk writing in a book, holding a pen, listen
to a teacher, describe what they are going to do is much
easier when they are medicated because they are not.it
sounds awful, but they are not necessarily inspired they
know they just need to sit down and do it if that makes sense
(T2)
Cog Changes in thinking
(Increased fixation
on thoughts)
15 (33%) Preoccupied by
doing things in
certain way
We have children who did a lot of.more collecting [things]
and sorting and ordering. And we had children who had pre-
occupation with thought -you know, repeating obsessional
thoughts (C9)
Fixated with own
thoughts
When you think. you feel like you think over and too much
on it. (AC4)
Cog Reduced creativity 13 (29%) Less creative If I’ve been shooting a film we’ve got lots of stuff going on and
it’s the kind of film that I know how to make very well, you
know, the kind of thing we do a lot, then I won’t take the
drugs at all. And while we’re doing all the editing and post
production I generally won’t take the drugs either because
the drugs are very, very good if you’ve got to do loads of
different meetings with clients and things like that, but they
are not that great if you want to think very creatively (AC5)
Overly logical I am not as creative with my thinking as I am without it
[.]When I am off my medication, I can be quite creative
especially solving things and looking at things in different
ways and when I am on medication it’s harder to do that; I
get quite logical and I come to that point where I am too
logical (AC3)
(continued)
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Table 4. (Continued)
Dom Subdomain
N (%) of
participants
reporting Statement Detailed illustrative quote
Cog Sensory overload 13 (29%) Senses
overpowering
Sometimes he is saying when you are not even shouting or not
shouting very loudly, he’ll say you are shouting at him. So I
don’t know, it may have an impact there. He says ‘‘you are
shouting, shouting all the time’’ and yet he’ll be shouting. He’ll
shout when he wants to. It’s okay for him to do that but he
doesn’t like anyone to raise their voice (P5)
Hypersensitive
to sight/sound/
taste
Yeah your touch and your smell and everything else is more
heightened, the taste buds . It messes up all your senses
really. The colours are more brighter. Yeah things are more
brighter. kinda strange (AC2)
Cog Attention/concentra-
tion (hyperfocusing
on tasks)
12 (27%) Focus too much
on tasks
My husband had to deal with everything cos I couldn’t put my
attention on all sorts of different things that I normally
would do. Normally I got all 4 [children] of them spinning
around me and now I deal with it to some degree, but on
meds I wasn’t dealing with it at all. Just didn’t wanna know
[.] I’d spend 15 hours putting together a presentation for
my MD (AC2)
Over-focus
on jobs
I’ll just sit there and do what I enjoy and get really fixed on
that, much more than I would normally do without my
medication. Things like eating, washing up, I seem to focus
a lot more on them than I would without my medication
(AC3).
Mood Increased anxiety 9 (20%) Anxious There’s this inner nag, it makes me feel like I am wasting my
time but I also feel like I can’t. Like I don’t want to stop. I
feel like there is some anxious feeling (AC6)
Feel on edge I can get more anxious at times. I have good days and bad
days. I think I suffer with anxiety anyway but there are days
when I think ‘‘I’m not going to take one today’’ because I
just know it will make me slightly worse. So if I’m having a
really off day then I would leave it because I know that it
can have an effect on anxiety (AC8)
Cog Memory 8 (18%) Forgetful Yes, I think he has probably got more forgetful. I have to tell
him more than once to do something. more like five times
sometimes. (P2)
Trouble
remembering
recent events
I will forget things all the time. I forget where my shoes are, I
forgot what lessons I need to go to on the day, what time it is
(AC1)
Cog Slower processing
speed (MPH slow
reaction time)
7 (16%) Loss of
competitive
edge
I have had a couple of young people, one of them was sporting
champion who didn’t take Ritalin before competition
because he felt it just dampened his competitive edge and
that he needed to be more ‘‘devil may care’’ to be able to
compete C2)
Became slower
to react
I find my reactions are a lot slower on tablets then off tablets. I
do kickboxing and I find it very hard to do the quick fighting
on tablets that I do off tablets[.] For your reactions to be
quick it has to be a natural thing that you do. Off a tablet I
see everything I see all the little things I hear all the little
things I am really supersensitive. On a tablet it dims it all
down, it puts a blanket over everything (AC4)
Mot External locus of
control (being good
attributed to
medication)
7 (16%) Became good Interestingly you sometimes get children who will say things
like ‘‘oh I haven’t had my tablet today so I am not going to
be good’’ or ‘‘I can’t be good today cos I haven’t had my
tablet’’ which obviously sounds rather horrifying to us.
Either they got that message from school or home or perhaps
they have come up with it themselves where they believe
they are only good because they are taking the tablet[.] I
give them MPH and they get the message that they are only
good and only acceptable and only likeable because they are
on MPH which is pretty horrific (C1)
(continued)
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Table 4. (Continued)
Dom Subdomain
N (%) of
participants
reporting Statement Detailed illustrative quote
Well behaved They sort of come in and said ‘‘I am so much happier now I’m
a good boy everyone likes me’’ but [.] are they just more
compliant with people or is there a fundamental shift in
cognition (C2)
Cog Changes in thinking
(increased rigidity
of thought)
7 (16%) Trouble
considering
others’
viewpoints
No.not able to take it in, other people’s point of view. I was
trying to listen to people, I was asking people for advice [.]
but now I think it’s more because I thought my decision was
right.like if they’d say ‘‘I think you should do this’’ I’d be
like ‘‘Well actually no I think we should do that’’ (AC2)
Unable to consider
different ways
of doing things
There is less negotiating and they do have very strong ideas
that can’t be changed [.] Those that are on it [MPH] do
seem to be the ones that do have the more sort of
unwavering ideas (T3)
Mot Lack of effort/engage-
ment in daily tasks
7 (16%) Difficult to start
routine or daily
tasks
Everyday tasks are more hard to get motivated about to start on
my medication than without. I find them easier to do without
MPH. I find it easier to finish them but I can’t start them. I:
What tasks do you find harder to start? AC3::just everyday
tasks that I find boring, like tidying up, cleaning up, things
that I have no interest in [.]I’ve got to plan to do hard stuff
when I am off my medication cos it’s easier to start (AC3)
Put less effort into
things
Things like going to the toilet. Lad in my class, when he is
medicated we have to remind him to do things like that.
Which is really strange, you have to say ‘‘it’s break time,
you need to go to the toilet, its lunch time you need to go to
the toilet, it’s home time, you need to go to the toilet.’’ It’s
not something I would have to do if he wasn’t medicated
(T2)
Cog Processing speed
(slower thinking)
6 (13%) Difficult to think
quickly
What the young person is saying is that I don’t want to have
that boring, detailed . I don’t want to have the analytical
depth; I want to have the free-thinking, whizzy brain stuff,
which is ideal for entrepreneurial thinking (C13)
Thinking more
slowly than
usual
It’s like they are sitting in honey, it becomes such a tedious,
slow process for them and you know that they would’ve got
yesterday in an instant, takes a really long time for them to
process that information. I find that if they are that way out,
they don’t retain their information at all. If they are at a
point where they are just repressed by that drug, they don’t
retain the information that they’ve just learnt (T2)
Mot Increased focus on
rewards/incentives/
external praise
6 (13%) Need to be
rewarded for
doing work
Q1: If he’s like ‘‘If I do this dad or do this mum will I get that
at the end of the week?‘‘ and you say ‘‘Yeah,’’ so he thinks a
lot about rewards. Interviewer: and was he like that before
Ritalin? P1: Not as much (P1)
Expect others to
praise or
reward me
For example, if they join a reading group, we have got the
treasure chest out to choose a present once they have
achieved a certain level of reading or whatever, but they
seem to be quite needy and ask right from the beginning
‘‘what will my prize be?’’ So it seems to be a longing to
already know what is going to happen, what the outcome is
going to be (T5)
Cog Attention/concentra-
tion (increased dis-
traction)
5 (11%) Distracted Basically I think normally what might happen is I’ll be doing
something complex and another thought will come into my
head and it might be something like . oh how long have I
got to do this left? It might be something related to the task,
but something will come in and that will distract you just
enough to let you forget it (AC6)
Trouble
concentrating
There are ones who have said they can’t concentrate, they can’t
pay attention[to a task] (C7)
AC, adult/child with ADHD; ADHD, attention-deficit/hyperactivity disorder; C, clinician; Cog, cognitive; I, Interviewer; Mot, motivation; P, parent, T,
teacher; number, participant number (e.g., P1, parent 1).
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children are most likely to develop adverse cognitive, motivational,
or mood-related adverse events (e.g., with co-occurring anxiety
symptoms).
Clinical Significance
The limitations above notwithstanding our tentative findings
extend some of the recent reports of adverse events of MPH in the
literature by specifically addressing the putative negative impact of
MPH treatment on the specific domains of cognitive, motivational,
and mood functioning with a broader range of participant groups.
Despite the more common experience of positive effects of MPH
therapy, for some individuals at least, the perceived negative im-
pact of MPH use on their thinking, mood, and motivation has po-
tential implications for treatment. Many clinicians interviewed in
this study noted that they did not routinely screen for these types of
adverse events and only recorded them if the patient spontaneously
reported them. Accordingly, the use of a standardized tool to gather
information about cognitive, motivational, and mood effects of
MPH in clinical practice may help to focus psychoeducational
approaches on respective findings and, thus, hopefully contribute to
medication adherence and treatment alliance (Adler and Nieren-
berg 2010). Moreover, a greater understanding of the potential
adverse events of medication on these important, but often over-
looked, areas will ultimately improve individualized patient care.
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